Tenax Therapeutics, Inc. (TENX)
| Market Cap | 67.01M -77.4% |
| Revenue (ttm) | n/a |
| Net Income | -65.76M |
| EPS | -1.38 |
| Shares Out | 53.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,284,852 |
| Open | 1.320 |
| Previous Close | 1.390 |
| Day's Range | 1.240 - 1.350 |
| 52-Week Range | 1.240 - 19.400 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 10.29 (+723.2%) |
| Earnings Date | Nov 5, 2026 |
About TENX
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TENX stock is "Buy." The 12-month stock price target is $10.29, which is an increase of 723.20% from the latest price.
News
What Should Tenax Therapeutics, Inc. Investors Know After 89.77% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Tenax Therapeutics, Inc. made misleading statements to investors from November 13, 2023 to August 7, 2026; lead plaintiff motions are due December 28, 2026 LOS ANGELES, Nov. 20, 2026 /...
DEADLINE ALERT for Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Lululemon Athletica, Inc (LULU): The Law Offices of Howard G.
Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Tenax Therapeutics, Inc., Everest Group, Ltd., and Lululemon Athletica, Inc Lead plaintiff deadline...
DEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd.
Investors in UP Fintech Holding Limited, Tenax Therapeutics, Inc., Everest Group, Ltd., and Yiren Digital Ltd. have upcoming deadlines to seek lead plaintiff appointment in pending securities class ac...
TENX Investors Have Rights - If You Lost Money Investing in Tenax Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Nov. 16, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquir...
Kaplan Fox Encourages Tenax Therapeutics, Inc. (TENX) Investors to Contact the Firm Before the Deadline on December 28, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - November 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) ("Tenax" or ...
Kaplan Fox Advises Tenax Therapeutics, Inc. (TENX) Investors to Act Before the Lead Plaintiff Deadline on December 28, 2026
New York, New York--(Newsfile Corp. - November 12, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") ...
What Does Tenax Therapeutics, Inc.'s 89.77% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Tenax Therapeutics, Inc. failed to disclose key facts to investors from November 13, 2023 through August 7, 2026; lead plaintiff deadline is December 28, 2026 BENSALEM TOWNSHIP, Pa., Nov....
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax...
Tenax Therapeutics reports Q3 EPS (31c), consensus (36c)
According to Stuart Rich, Chief Medical Officer of Tenax Therapeutics (TENX), “NT-proBNP and measures of PAP such as RVSP are independent biomarkers used in everyday diagnosis and treatment of patient...
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., No...
Tenax Therapeutics Earnings release: Q3 2026
Tenax Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Tenax Therapeutics Quarterly report: Q3 2026
Tenax Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Kaplan Fox Reminds Tenax Therapeutics, Inc. (TENX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on December 28, 2026
New York, New York--(Newsfile Corp. - November 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (...
Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith t...
Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Tenax Therapeutics, Inc. ("Tenax" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it ...
Tenax Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent trial data showed missed primary endpoint but strong biological effects, especially in sicker patients, with significant NT-proBNP and pressure reductions. Future trials will focus on enrolling less healthy patients to better demonstrate efficacy, with protocol adjustments and positive feedback from experts.
Tenax Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Tenax Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief ...
Guggenheim downgrades Tenax Therapeutics on clinical, regulatory uncertainty
As previously reported, Guggenheim downgraded Tenax Therapeutics (TENX) to Neutral from Buy with no price target While the LEVEL trial presentation at ESC indicated there may be a potential path…
Tenax Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Tenax Therapeutics (TENX) to Neutral from Buy.
Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103
Tenax Therapeutics (TENX) announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hypertension due to heart failure with preserved ejectio...
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112)
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
Tenax Therapeutics stock lost approximately 84% to 85% of its value in a single trading session after the Phase 3 LEVEL topline readout. SueWallSt notifies investors of a pending investigation into on...
Tenax Therapeutics downgraded to Neutral from Buy at Chardan
Chardan downgraded Tenax Therapeutics (TENX) to Neutral from Buy with a $5 price target down from $27, after the company announced that the LEVEL Phase III study missed its primary…
Tenax Therapeutics price target lowered to $4 from $35 at Canaccord
Canaccord lowered the firm’s price target on Tenax Therapeutics (TENX) to $4 from $35 and keeps a Buy rating on the shares. The firm noted the company reported that the…